AstraZeneca (LON:AZN) Receives “Buy” Rating from Shore Capital

AstraZeneca (LON:AZN)‘s stock had its “buy” rating reiterated by investment analysts at Shore Capital in a note issued to investors on Friday,Digital Look reports.

A number of other equities analysts also recently commented on the stock. JPMorgan Chase & Co. restated an “overweight” rating on shares of AstraZeneca in a research note on Wednesday, February 19th. Berenberg Bank reiterated a “buy” rating and set a GBX 140 ($1.80) target price on shares of AstraZeneca in a report on Monday, January 27th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, AstraZeneca presently has a consensus rating of “Moderate Buy” and an average price target of GBX 7,542.80 ($97.20).

AstraZeneca Price Performance

Shares of LON AZN opened at £119.58 ($154.10) on Friday. The firm has a market cap of £230.08 billion, a PE ratio of 32.78, a PEG ratio of 0.86 and a beta of 0.17. The company has a current ratio of 0.93, a quick ratio of 0.59 and a debt-to-equity ratio of 73.83. AstraZeneca has a 1-year low of GBX 9,670 ($124.61) and a 1-year high of £133.88 ($172.53). The company has a fifty day moving average price of £112.76 and a 200 day moving average price of £114.26.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.